Key Highlights
- Graft-versus-host disease is a potentially serious complication of allogeneic stem cell transplantation.
- Total allogenic transplant cases of graft-versus-host disease in the 7MM range from ~24,440 in 2022 to ~29,600 in 2032.
- Graft-versus-host disease is categorized into two types: acute and chronic graft-versus-host disease. In the 7MM, the acute graft-versus-host disease incident cases were ~10,340 in 2022, which are likely to increase to ~12,360 by 2032. Furthermore, in the 7MM, the 5-year prevalence of chronic graft-versus-host disease was ~23,080 in 2022, which is likely to increase to ~26,300 cases by 2032.
- Three major organs targeted by acute type are the skin (~71%), gastrointestinal tract (~79%), and liver (~21%). An assessment of the degree of involvement of these organs determines the severity of acute graft-versus-host disease.
- In the US, the grading-specific incident cases of acute graft-versus-host disease for Grade B, Grade C, and Grade D were ~3,140, ~1,280, and ~600, respectively, in 2022, which are likely to increase to ~3,930, ~1,600, and ~760, respectively, by 2032.
- The overall severity of chronic graft-versus-host disease is classified as mild, moderate, or severe based on organ-specific grading (number of organs and severity). Approximately ~45% of 5-year prevalent cases of chronic graft-versus-host disease belong to the moderate category.
- Skin (~59%), oral mucosa (~53%), eyes (~53%), lungs (~43%), liver (~29%), joints and fascia (~28%), and gastrointestinal (~23%) are the most often affected organs by chronic graft-versus-host disease. Genital seemed to be underestimated in chronic graft-versus-host disease organ grading (~5%).
- The mortality-adjusted treatment rate is used to estimate the number of living patients who are receiving treatment or who will be eligible for treatment. In 2022, the 7MM mortality-adjusted treated acute graft-versus-host disease patients were ~9,830 in first-line, and these cases are expected to increase to ~11,740 cases by 2032.
Geography Covered
- The United States
- EU4 (Germany, France, Italy, and Spain) and the United Kingdom
- Japan
Graft vs. Host Disease Understanding and Diagnostic Algorithm
Graft vs. Host Disease Overview
Graft vs. Host Disease is an immune condition that occurs after transplant procedures when immune cells (T cells) from the donor (known as the graft or graft cells) attack the recipient patient host's tissues (healthy cells); the disease is a side effect that is common after an allogeneic bone marrow transplant. In some cases, it can be even life-threatening. Before undergoing an allogeneic stem cell transplant, the patient will receive high doses of chemotherapy or radiation to destroy the diseased cells and prepare the body for the donor cells.The two main types of Graft vs. Host Disease are acute Graft vs. Host Disease and Chronic Graft vs. Host Disease. As an allogeneic transplant recipient, the patient might experience either form of Graft vs. Host Disease, either form, or neither. Approximately 30-50% of people generally develop acute Graft vs. Host Disease, and 10-70% develop chronic Graft vs. Host Disease and undergo an allogeneic transplant.
Acute Graft vs. Host Disease typically starts with the sudden outbreak of a red, inflamed rash on the palms, soles, face, ears, and shoulders. The rash can often become widespread and precede the onset of gastrointestinal or liver symptoms.
Chronic Graft vs. Host Disease also tends to start with a burning rash on the same parts of the body, although it can be more severe and cause blistering, peeling, and skin hardening. Gastrointestinal and liver symptoms can also develop, in addition to symptoms affecting other organ systems, including the eyes, lungs, joints, muscles, genitals, and nervous system.
Graft vs. Host Disease diagnosis
Graft vs. Host Disease can be challenging to diagnose because many symptoms occur with other conditions or diseases, none of which have anything to do with Graft vs. Host Disease. If treated presumptively without meeting specific diagnostic criteria, a person with Graft vs. Host Disease may be exposed to therapies that are not only unnecessary but can mask the true cause of the symptoms. In cases like these, a strict set of criteria governs the diagnosis of Graft vs. Host Disease.According to guidelines issued by the National Institutes of Health, the diagnosis of Graft vs. Host Disease typically requires at least one clinical sign of Graft vs. Host Disease paired with a confirmatory test of a pathologic feature of Graft vs. Host Disease (either involving the same or another organ). The confirmatory tests used to diagnose Graft vs. Host Disease may involve a biopsy, lab test, or imaging study. The tests may provide histological evidence of Graft vs. Host Disease (as seen by changes in cells under the microscope), serve as a biomarker of Graft vs. Host Disease (as seen by changes in lab values), or detect signs of gastrointestinal injury consistent with Graft vs. Host Disease. More than one test is sometimes needed.
Graft vs. Host Disease Epidemiology
As the market is derived using the patient-based model, the Graft-versus-host disease epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Total Hematopoietic Stem-cell Transplant Cases, Total Allogeneic Transplant Cases, Total Graft vs. Host Disease Cases by Types (Acute and Chronic), Total Incident Cases of Acute Graft vs. Host Disease by Grading and Organ Involvement, Total 5-year Prevalent Cases of Chronic Graft vs. Host Disease by Grading and Organ Involvement, Total Treated cases of Graft vs. Host Disease, and Mortality-adjusted Treated Cases of Graft vs. Host Disease in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2019 to 2032. The total cases of Graft vs. Host Disease in the 7MM comprised approximately 51,500 cases in 2022 and are projected to increase during the forecast period.- The total number of cases of Graft vs. Host Disease in the United States was around 23,100 cases in 2022.
- The US contributed to the largest Graft vs. Host Disease population, acquiring ~45% of the 7MM in 2022. Whereas Japan accounted for around 16% and Germany accounted for around 15% of the total population share, respectively, in 2022.
- According to the publisher's estimates, there were around 5,000 and 18,100 cases of acute and chronic Graft vs. Host Disease in the United States in 2022. These cases are projected to increase during the forecast period.
Scope of the Report
- The report covers a segment of key events, an executive summary, and a descriptive overview of Graft vs. Host Disease, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
- Comprehensive insight into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, and disease progression have been provided.
- A detailed review of current challenges in establishing diagnosis and diagnosis rate is provided.
Graft vs. Host Disease report insights
- Patient population
- Prevalence pattern
- Diagnosis rate
- Country-wise epidemiology distribution
Graft vs. Host Disease report key strengths
- Ten years forecast
- The 7MM coverage
- Graft vs. Host Disease epidemiology segmentation
Graft vs. Host Disease report assessment
- Epidemiology segmentation
- Current diagnostic practices
Key Questions Answered
Epidemiology Insights
- What are the disease risk and burdens of Graft vs. Host Disease? What will be the growth opportunities across the 7MM with respect to the patient population of Graft vs. Host Disease?
- What is the historical and forecasted Graft vs. Host Disease patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
- Why are only limited patients with symptoms treated?
- What factors are affecting the increase in the diagnosis of symptomatic cases?
Reasons to Buy
- The report will help develop business strategies by understanding the latest trends and changing epidemiology dynamics driving the Graft vs. Host Disease.
- Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
- To understand the perspective of Key Opinion Leaders around the current challenges with establishing the diagnosis and current diagnosis rate of the eligible patient pool.
Table of Contents
1. Key Insights2. Report Introduction4. Epidemiology Methodology5. Executive Summary of Graft-versus-host Disease9. Publisher Capabilities10. Disclaimer11. About the Publisher
3. Graft-versus-Host Disease: Patient Share (%) distribution
6. Disease Background and Overview
7. Epidemiology and Patient Population
8. Appendix
List of Tables
List of Figures
